Omada Health Posts $7 Million Net Income in Third Quarter of 2026
Key Facts
Omada Health posted net income of $7 million in the third quarter of 2026, compared with a net loss of $3 million in the same period of 2025, according to the company’s official results statement. The statement puts exact net income at about $6.551 million, versus an exact loss of $3.178 million a year earlier. The return to profitability coincided with total membership reaching 1.1 million, up 36% year over year. The company said membership growth reflects demand for its cardiometabolic care platform and momentum in enrollment in its diabetes and hypertension programs. Adjusted EBITDA was $12 million, compared with $2 million in the third quarter of 2025.
Co-CEO Sean Duffy attributed the strength of the business to the diabetes and hypertension programs, noting that the average member tenure in the programs reached a record of nearly two years and four months. That represents an increase of 10% year over year, according to the company’s account of Duffy’s remarks in the results statement. Revenue per member over the trailing twelve months also rose about 5% to $294. These metrics offer a picture of user-base growth and continued participation in the programs, alongside improved revenue per member. Cash and cash equivalents totaled $243 million as of September 30, 2026, according to the statement.
On its annual outlook, the company said the midpoint of its 2026 revenue guidance range represents growth of about 33% compared with 2025. It said the midpoint of its adjusted EBITDA guidance range reflects an improvement of about $27 million, or roughly five and a half times, from the prior year. This places the operating performance outlook among the metrics the company highlighted alongside its quarterly results. The statement did not provide the absolute values of the two guidance ranges in the information available here. Omada scheduled a call to discuss the results for November 5, 2026, at 1:30 p.m. Pacific time, or 4:30 p.m. Eastern time.
The results come ahead of an announced leadership transition at the company: Wei-Li Shao is set to become CEO on January 1, 2027. Founder and CEO Sean Duffy will move to the role of executive chairman, according to an earlier company announcement. The announcement ties the change to the start of 2027, after a period in which the current leadership will continue to run the company. The transition was mentioned in the context of the results, with Duffy’s third-quarter statement emphasizing the role of the diabetes and hypertension programs in driving growth. The information provided included no further details about the leadership transition arrangements.